XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition. Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM. There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas). In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study. This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Study Type
OBSERVATIONAL
Enrollment
50
No investigational drug will be administered to participants in this study.
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
RECRUITINGBoston Children's Hospital
Boston, Massachusetts, United States
RECRUITINGCincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
RECRUITINGChildren's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
RECRUITINGUPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
RECRUITINGIncidence rate of cholestasis
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.
Time frame: Up to Week 48
Point prevalence of cholestasis
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).
Time frame: Day 1
Prevalence of cholestasis
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).
Time frame: Up to 1 year
Genetic variants of MTM1
The association between genetic variants of MTM1 and cholestasis will be evaluated.
Time frame: Up to Week 48
Risk of cholestasis temporarily associated with environmental modifiers
Medication use, immunization history, infectious disease history and dietary habits will be collected.
Time frame: Up to Week 48
Hospitalizations
Frequency and reason for hospitalizations will be collected.
Time frame: Up to Week 48
Duration of Hospitalizations
Duration of hospitalization visits will be collected.
Time frame: Up to Week 48
Emergency room visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Hepatology specialist visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Scheduled/unscheduled office visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Non-study-specified home healthcare visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Surgeries/procedures
Frequency and type will be collected.
Time frame: Up to Week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.